Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Non Operating Income (2016 - 2025)

Guided Therapeutics' Other Non Operating Income history spans 13 years, with the latest figure at -$579000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 5690.0% to -$579000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$518000.0, a 3137.5% decrease, with the full-year FY2025 number at -$533000.0, down 2861.11% from a year prior.
  • Other Non Operating Income hit -$579000.0 in Q4 2025 for Guided Therapeutics, down from -$37000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for GTHP hit a ceiling of $763000.0 in Q3 2021 and a floor of -$579000.0 in Q4 2025.
  • Historically, Other Non Operating Income has averaged $9352.9 across 5 years, with a median of $1000.0 in 2022.
  • The widest YoY moves for Other Non Operating Income: up 9700.0% in 2025, down 5690.0% in 2025.
  • Tracing GTHP's Other Non Operating Income over 5 years: stood at $537000.0 in 2021, then tumbled by 97.95% to $11000.0 in 2022, then crashed by 372.73% to -$30000.0 in 2023, then surged by 66.67% to -$10000.0 in 2024, then crashed by 5690.0% to -$579000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for GTHP at -$579000.0 in Q4 2025, -$37000.0 in Q3 2025, and $98000.0 in Q1 2025.